TELO Q4 2023 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

TELOTelomir Pharmaceuticals, Inc. Common Stock

$46M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$1M

Net Income

-$9M

EPS (Diluted)

$-0.32

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$5M

Total Liabilities

$1M

Stockholders' Equity

$3M

Cash & Equivalents

$1,231

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$1M	-$487,096	-121.4%
Net Income	-$9M	-$487,096	-1814.9%